Role of vitamin D supplementation and vitamin D receptor in drug-resistant epilepsy: A double-blind placebo-controlled trial conducted in India.

What Was Tested

Researchers studied Vitamin D, K2, Magnesium and Zinc in this randomized controlled trial publication.

Who Took Part

By PubMed's age tags, the people studied were young adults, adults and middle-aged adults, both men and women.

This double-blind, placebo-controlled, parallel-group, adjunctive trial recruited patients from a tertiary care hospital in India.

How the Study Was Run

The design is described as randomized, double-blind, placebo-controlled, parallel-group and pilot.

The participants were allocated by chance, so the Vitamin D, K2, Magnesium and Zinc group and the comparison group should start out alike.

Blinding on both sides kept the participants and researchers unaware of who received Vitamin D, K2, Magnesium and Zinc.

The comparison arm used a placebo, so changes seen with Vitamin D, K2, Magnesium and Zinc could be set against what happens without it.

The Vitamin D, K2, Magnesium and Zinc group and the comparison group ran side by side rather than switching.

What Was Measured

The subject headings attached to it are India, Receptors, Calcitriol, Vitamin D, Drug Resistant Epilepsy, Dietary Supplements, Anticonvulsants and Vitamins.

The authors tagged it with the keywords HMGB1, drug‐resistant epilepsy, glial cell line–derived neurotrophic factor, neurotrophin‐3 and vitamin D receptor.

What This Means in Plain Language

The paper is a randomized, double-blind and placebo-controlled study of Vitamin D, K2, Magnesium and Zinc.

The abstract goes on to report its results in about 9 sentences; this page does not restate them, so read the paper for the findings and their limits.

The publication is from 2025 (Epilepsia), a journal based in United States.

More context: the Vitamin D, K2, Magnesium and Zinc compound page, all human trials.